Skip to content
10-Q

Quarterly Report

Dogwood Therapeutics, Inc. DWTX

0001104659-26-061938

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 33.63M sh
Shares Diluted Q1 2026 · Mar 31, 2026 33.54M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.44M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.59M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.68M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $13.23M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $6.52M
Stockholders Equity Q1 2026 · Mar 31, 2026 $80.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 $74.9M
Stockholders Equity Q1 2026 · Mar 31, 2025 $7.09M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$10.12M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.56M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.06M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.58M
Total Liabilities Q1 2026 · Dec 31, 2025 $15.27M
Current Assets Q1 2026 · Mar 31, 2026 $15M
Current Assets Q1 2026 · Dec 31, 2025 $8.43M
Total Assets Q1 2026 · Mar 31, 2026 $95.21M
Total Assets Q1 2026 · Dec 31, 2025 $90.17M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.15
Eps Diluted Q1 2026 · Mar 31, 2025 −$8.45
Eps Basic Q1 2026 · Mar 31, 2026 −$0.15
Eps Basic Q1 2026 · Mar 31, 2025 −$8.45
Sga Expense Q1 2026 · Mar 31, 2026 $2.41M
Sga Expense Q1 2026 · Mar 31, 2025 $1.99M
Rd Expense Q1 2026 · Mar 31, 2026 $2.67M
Rd Expense Q1 2026 · Mar 31, 2025 $2.44M
Net Income Q1 2026 · Mar 31, 2026 −$4.99M
Net Income Q1 2026 · Mar 31, 2025 −$10.92M
Operating Income Q1 2026 · Mar 31, 2026 −$5.08M
Operating Income Q1 2026 · Mar 31, 2025 −$4.43M